No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CCCC C4 Therapeutics
- 3.955
- -0.125-3.06%
Trading Jun 20 11:35 ET
272.13MMarket Cap-1668P/E (TTM)
4.070High3.920Low285.76KVolume4.070Open4.080Pre Close1.13MTurnover0.55%Turnover RatioLossP/E (Static)68.81MShares11.88052wk High1.05P/B207.51MFloat Cap1.06052wk Low--Dividend TTM52.47MShs Float51.210Historical High--Div YieldTTM3.68%Amplitude1.060Historical Low3.970Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is C4 Therapeutics (NASDAQ:CCCC) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares sinc
It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership ExperienceBruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...
We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Comments
$C4 Therapeutics(CCCC.US$
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
$C4 Therapeutics(CCCC.US$ doesnt look like its gonna go up by much ..
$C4 Therapeutics(CCCC.US$ C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment
1
The consensus is bullish on C4 Therapeutics, with increased forecasts and a higher price target. However, potential flags include dilutive stock issuance over the past year.
2
$C4 Therapeutics(CCCC.US$ forget to add in watchlist missed dip buying 4.90
2
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg